Evidence map›Paper›PMID 40799480›Full record

ArticleBio-protocol2025

Reprogramming White Fat Cells for Adipose Manipulation Transplantation (AMT) Therapy.

Kelly An, Yusuke Ito, Nadav Ahituv

Abstract read
In one paragraph

Article in Bio-protocol, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Kelly AnDepartment of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA, USA.
Yusuke ItoDepartment of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA, USA.
Nadav AhituvDepartment of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA, USA.

Funding

Functional characterization of obesity-associated OXTR enhancersR01DK124769 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI AHITUV, NADAV, VAISSE, CHRISTIAN · 2020 to 2024
$3.7M
Bioengineering adipocytes for cancer therapyR01CA283826 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Nadav Ahituv · 2024 to 2026
$1.9M
NCI NIH HHS R01 CA283826NIDDK NIH HHS R01 DK124769
6 · The paper itself

Abstract

Adipocytes are endocrine cells that function as the main energy storage in our body. They are commonly used in clinical procedures, including their removal via liposuction and transplantation in plastic surgery. Building on this, adipocytes can be used for ex vivo cellular manipulations, enabling therapeutic modifications that can provide beneficial clinical outcomes after transplantation. Here, we provide a detailed protocol on how to modify adipocytes and adipose organoids using CRISPR activation (CRISPRa), a technology termed adipose manipulation transplantation (AMT). Key features • This protocol is used to generate adipocytes and adipose organoids from human preadipocytes that can be genetically engineered for therapeutic purposes, including cancer metabolic therapy.

Indexed as

Adipocyte reprogrammingAdipocytesAdipose manipulation transplantation (AMT)Adipose organoidsCRISPR activationMetabolic cancer therapy

Identifiers

PMID40799480
PMCPMC12336856

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.